Table of Content

1. Introduction


2. Research Methodology


3. Executive Summary


4. Market Dynamics

4.1 Growth Drivers
4.2 Challenges


5. Global Narcolepsy Drugs Market


6. Market Share – Global Narcolepsy Drugs Market

6.1 By Therapeutic
6.2 By Disease
6.3 By Region


7. Therapeutic Analysis – Global Narcolepsy Drugs Market

7.1 Central Nervous System Stimulants
7.2 Tricyclic Antidepressants
7.3 Sodium Oxybate
7.4 Selective Serotonin Reuptake Inhibitor
7.5 Other Therapeutic Type


8. Disease - Global Narcolepsy Drugs Market

8.1 Daytime Extreme Sleepless
8.2 Cataplexia
8.3 Other Disease


9. Region – Global Narcolepsy Drugs Market

9.1 North America
9.2 Europe
9.3 Asia Pacific
9.4 Latin America
9.5 Middle East & Africa


10. Pipeline Drugs Analysis – Phase III

10.1 8.1 FT218: Avadel Pharmaceuticals

10.1.1 Product Description
10.1.2 Product Development Activities

10.2 8.2 JZP-258: Jazz Pharmaceuticals

10.2.1 Product Description
10.2.2 Product Development Activities


11. Pipeline Drugs Analysis – Phase II

11.1 AXS-12: Axsome Therapeutics

11.1.1 Product Description
11.1.2 Product Development Activities

11.2 THN102: Theranexus

11.2.1 Product Description
11.2.2 Product Development Activitie

11.3 BTD-001: Balance Therapeutics Inc

11.3.1 Product Description
11.3.2 Product Development Activities

11.4 Quilience: NLS Pharmaceutics Ltd.

11.4.1 Product Description
11.4.2 Product Development Activities

11.5 SUVN-G3031: Suven Life Sciences Ltd

11.5.1 Product Description
11.5.2 Product Development Activities

11.6 TAK-994: Takeda Pharmaceutical Company Limited

11.6.1 Product Description
11.6.2 Product Development Activities

11.7 ADAIR: Vallon Pharmaceuticals Inc

11.7.1 Product Description
11.7.2 Product Development Activities


12. Pipeline Drugs Analysis – Phase I

12.1 ONO-2909: Ono Pharmaceutical Co Ltd

12.1.1 Product Description
12.1.2 Product Development Activities

12.2.2 XW10172: XWPharma

12.2.1 Product Description
12.2.2 Product Development Activities


13. Pipeline Drugs Analysis – Lead Op / IND Enabling

13.1 OX2R Agonist (Oral): Centessa Pharmaceuticals Plc

13.1.1 Product Description
13.1.2 Product Development Activities
13.2.2 OX2R Agonist (Intranasal): Centessa Pharmaceuticals Plc

13.2 Product Description

13.2.1 Product Development Activities

13.3 TAAR1: F. Hoffmann-La Roche Ltd

13.3.1 Product Description
13.3.2 Product Development Activities

13.4 SLS-010: Seelos Therapeutics, Inc.

13.4.1 Product Description
13.4.2 Product Development Activities


14. Porters Five Forces

14.1 Overview
14.2 Bargaining Power of Buyers
14.3 Bargaining Power of Suppliers
14.4 Degree of Competition
14.5 Threat of New Entrants
14.6 Threat of Substitutes


15. Global Key Players Analysis

15.1 Teva Pharmaceutical Industries

15.1.1 Initiative / Strategy
15.1.2 Product Development
15.1.3 Net Sales

15.2 Jazz Pharmaceuticals Plc

15.2.1 Initiative / Strategy
15.2.2 Product Development
15.2.3 Net Sales

15.3 LIGAND PHARMACEUTICALS INC

15.3.1 Initiative / Strategy
15.3.2 Product Development
15.3.3 Net Sales

15.4 Hikma Pharmaceuticals PLC

15.4.1 Initiative / Strategy
15.4.2 Product Development
15.4.3 Net Sales

15.5 Takeda Pharmaceutical Company Limited

15.5.1 Initiative / Strategy
15.5.2 Development
15.5.3 Net Sales

15.6 HARMONY BIOSCIENCES

15.6.1 Initiative / Strategy
15.6.2 Development
15.6.3 Sales Analysis

15.7 Johnson & Johnson

15.7.1 Initiative / Strategy
15.7.2 Development
15.7.3 Sales Analysis

15.8 Arena Pharmaceuticals Inc.

15.8.1 Initiative / Strategy
15.8.2 Development
15.8.3 Sales Analysis



List of Figures

Figure-01: Global – Narcolepsy Drugs Market (Billion US$), 2017 – 2021
Figure-02: Global – Forecast for Narcolepsy Drugs Market (Billion US$), 2022 – 2027
Figure-03: Therapeutic – Central Nervous System Stimulants Market (Million US$), 2017 – 2021
Figure-04: Therapeutic – Forecast for Central Nervous System Stimulants Market (Million US$), 2022 – 2027
Figure-05: Therapeutic – Tricyclic Antidepressants Market (Million US$), 2017 – 2021
Figure-06: Therapeutic – Forecast for Tricyclic Antidepressants Market (Million US$), 2022 – 2027
Figure-07: Therapeutic – Sodium Oxybate Market (Million US$), 2017 – 2021
Figure-08: Therapeutic – Forecast for Sodium Oxybate Market (Million US$), 2022 – 2027
Figure-09: Therapeutic – Selective Serotonin Reuptake Inhibitor Market (Million US$), 2017 – 2021
Figure-10: Therapeutic – Forecast for Selective Serotonin Reuptake Inhibitor Market (Million US$), 2022 – 2027
Figure-11: Therapeutic – Other Therapeutic Type Market (Million US$), 2017 – 2021
Figure-12: Therapeutic – Forecast for Other Therapeutic Type Market (Million US$), 2022 – 2027
Figure-13: Disease – Daytime Extreme Sleepless Market (Million US$), 2017 – 2021
Figure-14: Disease – Forecast for Daytime Extreme Sleepless Market (Million US$), 2022 – 2027
Figure-15: Disease – Cataplexia Market (Million US$), 2017 – 2021
Figure-16: Disease – Forecast for Cataplexia Market (Million US$), 2022 – 2027
Figure-17: Disease – Other Disease Market (Million US$), 2017 – 2021
Figure-18: Disease – Forecast for Other Disease Market (Million US$), 2022 – 2027
Figure-19: North America – Narcolepsy Drugs Market (Million US$), 2017 – 2021
Figure-20: North America – Forecast for Narcolepsy Drugs Market (Million US$), 2022 – 2027
Figure-21: Europe – Narcolepsy Drugs Market (Million US$), 2017 – 2021
Figure-22: Europe – Forecast for Narcolepsy Drugs Market (Million US$), 2022 – 2027
Figure-23: Asia Pacific – Narcolepsy Drugs Market (Million US$), 2017 – 2021
Figure-24: Asia Pacific – Forecast for Narcolepsy Drugs Market (Million US$), 2022 – 2027
Figure-25: Latin America – Narcolepsy Drugs Market (Million US$), 2017 – 2021
Figure-26: Latin America – Forecast for Narcolepsy Drugs Market (Million US$), 2022 – 2027
Figure-27: Middle East and Africa – Narcolepsy Drugs Market (Million US$), 2017 – 2021
Figure-28: Middle East and Africa – Forecast for Narcolepsy Drugs Market (Million US$), 2022 – 2027
Figure-29: Teva Pharmaceutical Industries – Global Revenue (Million US$), 2017 – 2021
Figure-30: Teva Pharmaceutical Industries – Forecast for Global Revenue (Million US$), 2022 – 2027
Figure-31: Jazz Pharmaceuticals Plc – Global Revenue (Million US$), 2017 – 2021
Figure-32: Jazz Pharmaceuticals Plc – Forecast for Global Revenue (Million US$), 2022 – 2027
Figure-33: Novartis AG – Global Revenue (Million US$), 2017 – 2021
Figure-34: Novartis AG – Forecast for Global Revenue (Million US$), 2022 – 2027
Figure-35: LIGAND PHARMACEUTICALS INC – Global Revenue (Million US$), 2017 – 2021
Figure-36: LIGAND PHARMACEUTICALS INC – Forecast for Global Revenue (Million US$), 2022 – 2027
Figure-37: Hikma Pharmaceuticals PLC – Global Revenue (Million US$), 2017 – 2021
Figure-38: Hikma Pharmaceuticals PLC – Forecast for Global Revenue (Million US$), 2022 – 2027
Figure-39: Takeda Pharmaceutical Company Limited – Global Revenue (Million US$), 2017 – 2021
Figure-40: Takeda Pharmaceutical Company Limited – Forecast for Global Revenue (Million US$), 2022 – 2027
Figure-41: Johnson & Johnson – Global Revenue (Million US$), 2017 – 2021
Figure-42: Johnson & Johnson – Forecast for Global Revenue (Million US$), 2022 – 2027

List of Tables

Table-01: Global – Narcolepsy Drugs Market Share by Therapeutic (Percent), 2017 – 2021
Table-02: Global – Forecast for Narcolepsy Drugs Market Share by Therapeutic (Percent), 2022 – 2027
Table-03: Global – Narcolepsy Drugs Market Share by Disease (Percent), 2017 – 2021
Table-04: Global – Forecast for Narcolepsy Drugs Market Share by Disease (Percent), 2022 – 2027
Table-05: Global – Narcolepsy Drugs Market Share by Region (Percent), 2017 – 2021
Table-06: Global – Forecast for Narcolepsy Drugs Market Share by Region (Percent), 2022 – 2027